资讯

Sarepta shares crash as second patient dies after receiving its gene therapy
Shares of Sarepta Therapeutics closed down as much as 42% to hit a nine-year low of $18.30 on Monday after a second death of ...
STAT4 天
FDA reassures rare disease advocates that ‘being flexible’ is plan for gene therapy
Trump health officials signal eased FDA rules for rare disease gene therapy, but concerns linger over safety, oversight, and ...
Fierce Pharma3 天
Sarepta reports 2nd death after DMD gene therapy Elevidys, stops dosing in half of patients
A second patient has died following treatment with Sarepta Therapeutics’ Elevidys, raising more doubts about the Duchenne muscular dystrophy (DMD) gene therapy’s safety profile. | A second patient has ...
Science Daily5 天
Gene Therapy News
May 1, 2025 — To help achieve more precise control of gene therapy, engineers have designed a new control circuit that can keep gene expression levels within a target range. The method could be ...
Sickle cell disease cured? Ohio State celebrates big win via innovative gene therapy
Some doctors told him he'd live with the disease forever, but Khaled Alsheebani never stopped believing treatments would ...
BIRAC in pact with Miltenyi Biotec India to boost India's capabilities in cell & gene therapy
BIRAC and Miltenyi Biotec India have joined forces to elevate India's standing in cell and gene therapy (CGT). The ...
Sarepta shares tumble on second patient death after gene therapy treatment
By Christy Santhosh and Bhanvi Satija (Reuters) -Shares of Sarepta Therapeutics slumped 36% in premarket trading on Monday after the company reported the death of a second patient in three months who ...
90.5 WESA3 天
Penn researchers identify new potential gene therapy for glioblastoma brain cancer
Glioblastoma has been deadly and hard to treat, but researchers say they’ve made progress with bivalent CAR T-cell therapy ...